2027 Future Talent Program – Packaging Component Engineering – Co-Op
MSD
Summary
The Future Talent Program features Cooperative (Co-op) education that lasts up to 6 months and will include one or more projects. The co-op assignment will support our Manufacturing Division’s primary U.S. Packaging site in Wilson, North Carolina.
Job description
Key Learning & Development
- Primary and secondary packaging development and testing for solid oral dose, sterile and medical device/combination products
- Packaging equipment development and qualification
- Packaging processes and controls
- Packaging related documentation and regulations
- Assist in ad hoc response to floor support
- Initiate and manage supplier incident cases for component issues identified in Operations
- Participate in component investigations and travel to supplier's as needed
- Support in all packaging engineering activities as needed for all packaging component engineers including but not limited to engineering studies, machine trials, and profile and specification development
Requirements
- Currently pursuing degree in Packaging Science, Packaging Engineering
- Currently enrolled in an academic program and returning to university following this co-op assignment to complete credit requirements for graduation
- Available for full time employment for a period of six months. Targeted timeframe is 31 May 2027 to 17 Dec 2027
- Strong project management, problem solving, organizational, technical writing and communication skills
- GPA of 3.0 or higher
Company overview
MSD, known as Merck Sharp & Dohme outside the United States and Canada, is a global research-intensive biopharmaceutical company headquartered in Rahway, New Jersey. Founded in 1891, the company has established itself as one of the world's leading pharmaceutical corporations with a rich history spanning over 130 years. MSD operates as the international division of Merck & Co., Inc., focusing on the discovery, development, manufacturing, and marketing of innovative medicines, vaccines, biologic therapies, and animal health products. The company's extensive portfolio includes groundbreaking treatments in oncology, infectious diseases, cardiology, diabetes, and vaccines, with notable products such as Keytruda (pembrolizumab) for cancer immunotherapy, Gardasil for HPV prevention, and Januvia for diabetes management. MSD maintains a strong commitment to research and development, investing significantly in scientific innovation to address unmet medical needs worldwide. With approximately 75,000 employees globally, the company operates through four main segments: pharmaceuticals, animal health, healthcare services, and strategic alliances. MSD's mission centers on using leading-edge science to save and improve lives around the world, guided by the principle that medicine is for people, not profits.